Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
Cambridge, UK, 12 October 2022 - Sareum Holdings plc (AIM: SAR), a clinical stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces that it has been informed by Sierra Oncology, Inc. ("Sierra") (a subsidiary of GSK plc ("GSK") that it intends to return the rights for SRA737 to the CRT Pioneer Fund LP ("CPF").
Now that's a bit of a curve ball
HBD
It's this quote that stood out for me:
"why should large pharmaceutical companies bother with the time and expense of developing their own drugs when they can buy a partially-developed drug for less than the cost (and much less risk) than developing one themselves?"
Hi HBD
A bit like an expectant mother at the end of her pregnancy ... She knows the baby is coming but not the time and date ... not quite sure why SAR have not announced the CTA approval but guess there are "compelling" reasons
Totally agree RMM the recent increases are hardly demand driven ... so the MMs are doing what they do best ... Market Manipulation ... but who cares as long as its in the right direction ... unless of course you're short ... LH&K Mafuta
TBH the close today took me a little by surprise ... but a pleasant one ... Something is happening for such a rise and like others I'm looking forward to next week ... It could be quite exciting ... Have a good weekend everyone ... LH&K Mafuta
£50K is a fair amount of skin to put in ... well done Mo that's agraet vote of confidence.